Physician profile
Rohit A Marawar
NPI 1447415526
$59,812.08
in general payments reported to CMS, 2019-2025
16 companies · $40K in 2025
The $40K reported for 2025 was more than what 96% of Clinical Neurophysiology providers received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $2,312 · 2021: $27.67 · 2022: $105 · 2023: $8,625 · 2024: $8,527 · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Travel and Lodging: $7,623 · Consulting Fee: $6,140 · Food and Beverage: $3,181 · Education: $18.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,927.83 |
| Travel and Lodging | $7,623.03 |
| Consulting Fee | $6,140.00 |
| Food and Beverage | $3,180.93 |
| Education | $18.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $46,006.07 | 2024-2025 | Valtoco |
| Sk Life Science, INC. | $6,338.18 | 2020-2025 | Xcopri |
| Eisai INC. | $5,278.66 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $1,260.79 | 2024-2025 | |
| Ucb, INC. | $339.76 | 2019-2021 | |
| Livanova USA, INC. | $175.51 | 2020-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Neuropace, INC. | $153.84 | 2024 | |
| Sunovion Pharmaceuticals INC. | $122.19 | 2019 | |
| Novo Nordisk INC | $70.66 | 2024 | |
| Aquestive Therapeutics, INC. | $19.68 | 2019 | |
| Aucta Pharmaceuticals, INC. | $19.12 | 2025 | Motpoly Xr |
| Portola Pharmaceuticals, LLC | $15.02 | 2019 | |
| Zogenix INC. | $12.60 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Marawar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.